Slide 1: First Quarter Fiscal 2027 Results
First Quarter Fiscal 2027 Results August 6, 2026 © 2026 Haemonetics Corporation
Slide 2: Q1 Fiscal 2027 Conference Call Detail
Q1 Fiscal 2027 Conference Call Detail Conference call will take place at CONFERENCE 8:00 a.m. ET on August 6, 2026, and CALL SPEAKERS can be accessed via live webcast: Link or teleconference : Link . The earnings release, accompanying Chris Simon slides and a replay of the conference President & CEO
Slide 3: Important Information
Important Information Safe Harbor for Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934. Forward - looking statements do not relate strictly to h
Slide 4: Q1 Fiscal 2027 Highlights
Q1 Fiscal 2027 Highlights Broad - based Executing Building a Profitable Growth Our Strategy Higher - quality Business All three growth platforms Accelerating Persona ® PLUS Multiple growth platforms contributed to 6% organic adoption strengthens the are driving a more durable revenue and 4% adjusted
Slide 5: Revenue by Business Unit
Q1 Fiscal 2027 Revenue by Business Unit REVENUE REPORTED ORGANIC Q1 2027 Q1 2026 (in millions) GROWTH GROWTH 1 (in millions) Plasma $155.5 $145.1 7.2% 8.2% $321 $339 Other 2 $35.8 $36.7 (2.4%) (2.8%) Apheresis $191.3 $181.7 5.3% 6.0% MedSurg Interventional $59.9 $58.5 2.5% 2.8% Technologies 3 Aphere
Slide 6: Financial Review
Q1 Fiscal 2027 Financial Review GAAP RESULTS NON - GAAP RESULTS Q1 2027 Q1 2026 Y/Y Q1 2027 Q1 2026 Y/Y Adjusted Gross Margin % 59.8% 59.8% - bps 60.4% 60.8% - 40bps Gross Margin % Adjusted Operating Margin % 16.9% 16.8% +10bps 23.4% 24.1% - 70bps Operating Margin % Adjusted Net Net Income Margin %
Slide 7: Segment Performance
Q1 Fiscal 2027 Segment Performance APHERESIS MEDSURG Q1 2027 Q1 2026 Y/Y Q1 2027 Q1 2026 Y/Y 5.3% 6.0% reported / reported / Revenue $191.3M $181.7M Revenue $148.1M $139.7M 6.0% 5.9% organic organic Adjusted Adjusted 29.6% 32.6% - 300bps 15.3% 13.2% +210bps Operating Margin % ¹ Operating Margin % ¹
Slide 8: Balance Sheet and Cash Flow Metrics
Balance Sheet and Cash Flow Metrics CASH FROM OPERATIONS 6/27/26 3/28/26 (in millions) (dollars in millions) $328 Cash & cash equivalents $223 $245 $81 $227 Working capital $548 $552 $63 Total debt $1,174 $1,225 $247 Net debt 1 $951 $980 $52 $13 $17 $164 $39 $15 2 $2 Available credit $749 $749 Q1 FY
Slide 9: Full-Year Fiscal 2027 Guidance
Full - Year Fiscal 2027 Guidance GUIDANCE AS OF GUIDANCE AS OF MAY 7, 2026 3 AUGUST 6, 2026 Reported Revenue 4 – 7% 5 – 8% 53rd Week Impact (~2%) (~2%) Currency Impact 0 – 1% 0 – 1% Organic Revenue 1 3 – 6% 4 – 7% Apheresis LSD Growth LSD to MSD Growth MedSurg MSD Growth MSD Growth 50 – 100 bps expa
Slide 10: Appendices
Appendices © 2026 Haemonetics Corporation
Slide 11: Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates
Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates Reported Currency Acquisitions & Organic ($ millions) Q1 2027 Q1 2026 growth impact Divestitures 1 growth 2 Plasma $155.5 $145.1 7.2% 0.1% (1.1%) 8.2% Other 3 $35.8 $36.7 (2.4%) 0.4% – (2.8%) Apheresis $191.3 $181.7 5.3% 0.2% (0.9%)
Slide 12: Appendix B: Reconciliation of GAAP to Non-GAAP Financial Results
Appendix B: Reconciliation of GAAP to Non - GAAP Q1 Fiscal 2027 Financial Results Interest and Provision Earnings Operating Operating Gross profit other income (benefit) for Net income per diluted ($ millions) expenses income (expense) income taxes share Reported $202.8 $145.3 $57.5 ($9.9) $14.6 $33
Slide 13: Appendix B: Reconciliation of GAAP to Non-GAAP Financial Results (Q1 FY2026)
Appendix B: Reconciliation of GAAP to Non - GAAP Q1 Fiscal 2026 Financial Results Interest and Earnings Operating Operating Provision for Net income Gross profit other income per diluted ($ millions) expenses income (loss) income taxes (loss) (expense) share Reported $192.2 $138.4 $53.9 ($8.7) $11.1
Slide 14: Appendix C: Reconciliation of Cash Flows
Appendix C: Reconciliation of Cash Flows ($ millions) Q1 2027 Q1 2026 Free Cash Flow Reconciliation Cash provided by operating activities $52.3 $17.4 Capital expenditures ($7.9) ($3.8) Additions to Haemonetics equipment ($5.6) ($11.5) Proceeds from sale of property, plant and equipment $0.2 $0.3 Fre
Slide 15: Appendix D: Reconciliation of Segment Operating Income (1 of 2)
Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2) ($ millions) Q1 2027 Q1 2026 Net revenues: Apheresis $191.3 $181.7 MedSurg $148.1 $139.7 Total net revenues $339.4 $321.4 Significant segment expenses and operating performance: Apheresis Cost of goods so
Slide 16: Appendix D: Reconciliation of Segment Operating Income (2 of 2)
Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2) ($ millions) Q1 2027 Q1 2026 Corporate and unallocated expenses Amortization of acquired assets ($10.2) ($13.8) Integration and transaction costs ($2.7) ($2.7) Restructuring and restructuring related cost
Slide 17: Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results
Appendix E: Reconciliation of GAAP to Non - GAAP of TTM Financial Results 1 TTM Q1 TTM Q1 FY27 Net FY26 Net ($ millions) income income (loss) (loss) Reported $96.3 $163.3 Amortization of acquired intangible assets $32.6 $35.4 Amortization of fair value inventory step up $2.6 $9.2 Acquisition, Integr